Embrella Cardiovascular, Inc. Completes Series A Financing of 2.3 Million Dollars

MALVERN, Pa.--(Business Wire)--Embrella Cardiovascular, Inc. today announced that it has
completed its initial round of funding, raising 2.3 million dollars.

Included in this round of financing were: The "MedFocus Funds,"
Irvine, CA; BioStar Fund, Petoskey, MI; and Zeke, LP, Berwyn, PA. Also
included in this round were the founders and Angel Investors.

Embrella's Chairman and co-founder, Jeffrey F. O'Donnell
commented, "It is our belief that Embrella Cardiovascular will change
the standard of care for performing a variety of endovascular
procedures of the heart and thoracic aorta by significantly reducing
the risk of stroke currently associated with these procedures."

O'Donnell further commented, "We are grateful to the early stage
investors and our individual investors for their participation in this
initial round of funding. Embrella's Board is focused on accelerating
the design and developmental phase of its device and committed to
recruiting the brightest and best to ensure success."

Embrella's inventor and co-founder, Dr. Judith Carpenter notes,
"We are extremely excited about the Embrella device and its potential
to prevent embolic strokes and thus decrease the morbidity and
mortality rates of patients undergoing cardiovascular procedures. We
have made great progress in design thus far and will now accelerate
the product development."

About Embrella

Embrella Cardiovascular, Inc., based in Malvern, Pennsylvania, is
an early stage company dedicated to developing a unique, proprietary
system to enhance embolic cerebral protection, enabling
interventionalists to reduce the frequency of embolic strokes during
cardiovascular procedures.

Embrella Cardiovascular, Inc.
Company Contact:
Jeffrey O'Donnell, Chairman
610-304-0942
610-240-4769
odonnellx@comcast.net

Copyright Business Wire 2008